Company intelligence / Profile preview
Carbon Biosciences
Lexington, Massachusetts, United Statescarbonbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Carbon Biosciences has demonstrated preclinical proof-of-concept for its lead candidate CGT‑001 in cystic fibrosis models, showing upper airway tissue tropism and repeatable dosing. The company’s proprietary parvovirus-based gene therapy platform aims to overcome limitations of current AAV vectors by enabling larger payloads and reduced immune response. No clinical results have been published yet.
- Therapeutic areas
- PulmonologyCardiovascularRare Diseases
- Modalities
- Gene therapy (parvovirus-derived vectors)Genetic medicines (potentially across multiple modalities)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Cystic Fibrosis Foundation (investor/partner)
Beyond the preview
Go deeper on Carbon Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carbon Biosciences.